Sort   by:  
 Page size 
ProteomicsLow-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Potential Targets for Cancer Immunotherapy
Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but also trigger T cell-mediated immunity, which might be mediated by the qualitative and quantitative changes in human leukocyte antigen (HLA) ligands on the cancer cell surface. We investigated the effects of CDK4/6i, Abema...
ORGANISM(S): Homo sapiens (Human) 
2021-09-10 | PXD024965 | Pride
Abemaciclib Palbociclib Breast cancer Cdk4/6 inhibition Mhc ligand 
MetabolomicsCascading effects of root microbial symbiosis on the development and metabolome of the insect herbivore Manduca sexta L

Root mutualistic microbes can modulate the production of plant secondary metabolites affecting plant–herbivore interactions. Still, the main mechanisms underlying the impact of root mutualists on herbivore performance remain ambiguous. In particular, little is known about how changes in the plant...

2023-09-12 | MTBLS2700 | MetaboLights
UnknownA review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Not available
S-EPMC9437144 | biostudies-literature
UnknownHi-C Identifies Complex Genomic Rearrangements and TAD-Shuffling in Developmental Diseases.
Not available
S-EPMC7273525 | biostudies-literature
ProteomicsAutomated Phosphopeptide Enrichment for Gram Positive Bacteria
Protein phosphorylation in prokaryotes has gained more attention in recent years as several studies linked it to regulatory and signalling functions indicating an importance similar to protein phosphorylation in eukaryotes. Studies on bacterial phosphorylation have so far been conducted using manual...
ORGANISM(S): Listeria monocytogenes EGD 
2021-08-26 | PXD025459 | Pride
Bravo assaymap  fe(iii)-imac  tio2  automation  phosphopeptide enrichment  phosphoproteomics  quantification  listeria monocytogenes  bacillus subtilis  streptococcus pyogenes 
UnknownHealth-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.
Not available
S-EPMC12010963 | biostudies-literature
UnknownVariants in PUS7 Cause Intellectual Disability with Speech Delay, Microcephaly, Short Stature, and Aggressive Behavior.
Not available
S-EPMC6288278 | biostudies-literature
UnknownRELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Not available
S-EPMC8763844 | biostudies-literature
UnknownAdjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
Not available
S-EPMC12684762 | biostudies-literature
UnknownRationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Not available
S-EPMC10233570 | biostudies-literature
Sort   by:  
 Page size